The company was testing its therapy, cibotercept, in patients with pulmonary arterial hypertension (PAH) - a rare disease ...

Oppenheimer adjusted its price target on Keros Therapeutics (NASDAQ:KROS) shares, reducing it significantly to $23.00 from ...

Keros Therapeutics (KROS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in ...

BofA analyst Jason Zemansky lowered the firm’s price target on Keros Therapeutics (KROS) to $32 from $33 and keeps a Buy rating on the shares.

Analyst Jason Zemansky of Bank of America Securities reiterated a Buy rating on Keros Therapeutics (KROS – Research Report), reducing the price ...

Scotiabank (TSX:BNS) analysts revised the price target for Keros Therapeutics (NASDAQ:KROS) shares, reducing it to $41 from ...

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

Keros Therapeutics, Inc. has announced a voluntary halt in dosing for the Tropos trial, a phase 2 clinical trial of ...

Hinge Bio raises $30M Series A for lupus drug; Keros halts trial dosing; Inflammasome reports eye treatment data; J&J files bladder cancer therapy; Verastem licenses KRAS drug ...

The month of December 2024 saw a variety of biotech deals take place to advance therapies across different stages in ...

JPMorgan Chase & Co. JPM reported upbeat fourth-quarter FY24 results. Reported revenue rose 11% year-on-year to $42.8 billion. Net revenue (managed) was $43.7 billion (+10% Y/Y), beating the consensus ...

European shares were higher today. The eurozone's STOXX 600 surged 1.27%, Germany's DAX 40 gained 1.53% and France's CAC 40 gained 0.95%. Spain's IBEX 35 Index gained 1.20%, while London's FTSE 100 ...